The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them.
Appl Microbiol Biotechnol
; 104(19): 8231-8242, 2020 Oct.
Article
em En
| MEDLINE
| ID: mdl-32816087
ABSTRACT
Oncolytic virus (OV) immunotherapy is characterized by viruses which specifically target cancer cells and cause their cytolysis. They provide a unique and promising new tool for the eradication of cancer as they interact with and affect the tumor microenvironment (TME), vasculature, and immune system. Advancements of genetic engineering have allowed for these viruses to be armed in such a way to have enhanced targeting, strong immunomodulation properties, and an ability to modify the TME. However, there are still major limitations in their use, mostly due to difficulties in delivering the viral particles to the tumors and in ensuring that the immunomodulatory properties are able to stimulate the host immune response to mount a complete response. Using novel delivery systems and using OVs as a complementary therapy in a combinatorial treatment have shown some significant successes. In this review, we discuss the major issues and difficulties in using OVs as anti-tumor agents and some of the strategies put in place so far to overcome these limitations. KEY POINTS ⢠Oncolytic viruses (OVs) infect cancer cells and cause their cytolysis. ⢠The major limitations in using OVs as anti-tumor therapy were discussed. ⢠The potential strategies to overcome these limitations were summarized.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Vírus Oncolíticos
/
Terapia Viral Oncolítica
/
Neoplasias
Limite:
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article